Remove 2021 Remove Licensing Remove Trials
article thumbnail

Actithera draws new investors to radiopharma drug pitch

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Dive Brief Actithera draws new investors to radiopharma drug pitch The four-year-old biotech raised about $75 million in a Series A round that involved nine venture capital firms.

Drugs 156
article thumbnail

From siloed data to breakthroughs: multimodal AI in drug discovery

Drug Target Review

Clinical genomics, powered by NGS, enables more precise target validation, improved patient stratification and optimised trial design, ultimately aiming to increase PoS. Only in this way can AI reach its full potential in accelerating drug discovery and improving trial success rates. Highlighting data integration.

Drugs 65
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Inavolisib

New Drug Approvals

19] Society and culture Legal status In October 2024, the US Food and Drug Administration (FDA) approved inavolisib for the treatment of PIK3CA -mutant breast cancer based on the results from the INAVO120 trial. [3] Vanhaesebroeck B, Perry MW, Brown JR, Andr F, Okkenhaug K (October 2021). 22 June 2021. 3 November 2006.

FDA 57
article thumbnail

Zilucoplan

New Drug Approvals

Retrieved 24 June 2021. 6] [9] [10] It is a complement inhibitor that is injected subcutaneously (under the skin). [6] 6] Zilucoplan is a cyclic peptide that binds to the protein complement component 5 (C5) and inhibits its cleavage into C5a and C5b. [11] It is a macrocycle, a homodetic cyclic peptide and a polyether. 24 September 2024. .

FDA 57
article thumbnail

Taletrectinib

New Drug Approvals

1] [3] History The efficacy of taletrectinib to treat ROS1-positive non-small cell lung cancer was evaluated in participants with locally advanced or metastatic, ROS1-positive non-small cell lung cancer enrolled in two multi-center, single-arm, open-label clinical trials, TRUST-I (NCT04395677) and TRUST-II (NCT04919811). [3] 12 June 2025.

article thumbnail

Pirtobrutinib

New Drug Approvals

13] Efficacy was evaluated in BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobrutinib monotherapy that included 120 participants with mantle cell lymphoma previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. [4] 6] The same trial was used to assess safety and efficacy. [6] 12 (5): 80.

article thumbnail

Crinecerfont

New Drug Approvals

2] History Crinecerfont’s approval is based on two randomized, double-blind, placebo-controlled trials in 182 adults and 103 children with classic congenital adrenal hyperplasia. [2] 2] In the first trial, 122 adults received crinecerfont twice daily and 60 received placebo twice daily for 24 weeks. [2] 2021 Nov 30;186(1):R1-R14.

FDA 62